Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne

International Journal of Dermatology

Volumn 49, Issue 12, 2010, Pages 1440-1444

  Tunca, Mustafa ^a   Akar, Ahmet ^a   Ozmen, Ibrahim ^a   Erbil, Hakan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ERYACNE; ERYTHROMYCIN; NADEXA; NADIFLOXACIN; UNCLASSIFIED DRUG;

ACNE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; DRY SKIN; ERYTHEMA; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN BURNING SENSATION;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ERYTHROMYCIN; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; QUINOLIZINES; TURKEY; YOUNG ADULT;

EID: 78649419067     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04601.x     Document Type: Article

References (12)

1. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: a status report. Dermatol Clin 2009; 27: 1-15.
2. Jain A, Sangal L, Basal E, et al. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J 2002; 8: 2.
3. Kawabata S, Ohguro K, Mukai F, et al. Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 1: in vitro antibacterial activity. Chemotherapy 1989; 37: 1160-1178.
4. Alba V, Urban E, Angeles Dominguez M, et al. In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany. Int J Antimicrob Agents 2009; 33: 272-275.
5. Kuwahara K, Kitazawa T, Kitagaki H, et al. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci 2005; 38: 47-55.
6. Murata K, Sugita K, Kobayashi M, et al. Nadifloxacin downmodulates antigen-presenting functions of epidermal Langerhans cells and keratinocytes. J Dermatol Sci 2006; 42: 91-99.
7. O'Brien SC, Lewis JB, Cunliffe WJ. The Leeds revised acne grading system. J Dermatol Treat 1998; 9: 215-220.
8. Tucker SB, Tausend R, Cochran R, Flannigan SA. Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. Br J Dermatol 1984; 110: 487-492.
9. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant?: implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003; 4: 813-831.
10. Cunliffe WJ, Holland DB, Jeremy A. Comedone formation: etiology, clinical presentation, and treatment. Clin Dermatol 2004; 22: 367-374.
11. Inui S, Nakao T, Itami S. Modulation of androgen receptor transcriptional activity by anti-acne reagents. J Dermatol Sci 2004; 36: 97-101.
12. Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol 2006; 16: 48-55.